Business Context and Reporting Period
Company: Indivior Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 12, 2026
Event: Announcement of a proposed offering of convertible senior notes due 2031.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, existing debt levels, or liquidity ratios. This report focuses solely on the announcement of a new financing event.
Material Changes
The primary material change is the initiation of a proposed capital raise through the issuance of convertible senior notes due 2031. No comparative financial data or changes to prior period results are disclosed in this document.
Guidance, Outlook, and Risks
- Offering Details: The Company announced the launch of convertible senior notes due 2031.
- Legal Disclaimer: The 8-K and the accompanying press release (Exhibit 99.1) do not constitute an offer to sell or a solicitation of an offer to buy the Notes or any shares of common stock issuable upon conversion.
- Management Commentary: No specific outlook or commentary on operational performance is included in this filing.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific terms of the convertible notes, including interest rate, conversion price, and total offering size.
- Verify the final prospectus or pricing terms once the offering is completed.
- Assess the impact of the new debt and potential equity dilution on the Company's capital structure.